Display options
Cite
Zhang G, Zhang Y, Yang J, et al. Altered serous levels of monoamine neurotransmitter metabolites in patients with refractory and non-refractory depression. Neural Regen Res. 2012;7(14):1113-8doi: 10.3969/j.issn.1673-5374.2012.14.011.
Zhang, G., Zhang, Y., Yang, J., Hu, M., Zhang, Y., & Liang, X. (2012). Altered serous levels of monoamine neurotransmitter metabolites in patients with refractory and non-refractory depression. Neural regeneration research, 7(14), 1113-8. https://doi.org/10.3969/j.issn.1673-5374.2012.14.011
Zhang, Guiqing, et al. "Altered serous levels of monoamine neurotransmitter metabolites in patients with refractory and non-refractory depression." Neural regeneration research vol. 7,14 (2012): 1113-8. doi: https://doi.org/10.3969/j.issn.1673-5374.2012.14.011
Zhang G, Zhang Y, Yang J, Hu M, Zhang Y, Liang X. Altered serous levels of monoamine neurotransmitter metabolites in patients with refractory and non-refractory depression. Neural Regen Res. 2012 May 15;7(14):1113-8. doi: 10.3969/j.issn.1673-5374.2012.14.011. PMID: 25722703; PMCID: PMC4340026.
Copy Download .nbib Format: NLM
Share it on

Neural Regen Res. 2012 May 15;7(14):1113-8. doi: 10.3969/j.issn.1673-5374.2012.14.011.

Altered serous levels of monoamine neurotransmitter metabolites in patients with refractory and non-refractory depression.

Neural regeneration research

Guiqing Zhang, Yanxia Zhang, Jianxia Yang, Min Hu, Yueqi Zhang, Xia Liang

Affiliations

  1. Department of Rehabilitation and Psychology, the First Affiliated Hospital of Shihezi University Medical College, Shihezi 832008, Xinjiang Uygur Autonomous Region, China.

PMID: 25722703 PMCID: PMC4340026 DOI: 10.3969/j.issn.1673-5374.2012.14.011

Abstract

The study examined plasma metabolite changes of monoamine neurotransmitters in patients with treatment-resistant depression (TRD) and non-TRD before and after therapy. All 30 TRD and 30 non-TRD patients met the diagnostic criteria for a depressive episode in accordance with the International Classification of Diseases, Tenth Revision. Before treatment, and at 4, 6, and 8 weeks after treatment, the plasma metabolite products of monoamine neurotransmitters in TRD group, including 5-hydroxyindoleacetic acid, 3-methoxy-4-hydroxyphenyl ethylene glycol and homovanillic acid, were significantly lower than those in the non-TRD group. After two types of anti-depressive therapy with 5-serotonin and norepinephrine reuptake inhibitor, combined with psychotherapy, the Hamilton Depression Rating Scale scores were significantly reduced in both groups of patients, and the serous levels of 5-hydroxyindoleacetic acid and 3-methoxy-4-hydroxyphenyl ethylene glycol were significantly increased. In contrast, the homovanillic acid level exhibited no significant change. The levels of plasma metabolite products of peripheral monoamine neurotransmitters in depressive patients may predict the degree of depression and the therapeutic effects of treatment.

Keywords: 3-methoxy-4-hydroxyphenyl ethylene glycol; 5-hydroxyindoleacetic acid; homovanillic acid; monoamine neurotransmitter; treatment-resistant depression

References

  1. Expert Opin Investig Drugs. 2009 Nov;18(11):1753-64 - PubMed
  2. Nat Rev Neurosci. 2006 Feb;7(2):137-51 - PubMed
  3. Neurotox Res. 2004;6(3):233-44 - PubMed
  4. Psychopharmacology (Berl). 1998 Jul;138(1):1-8 - PubMed
  5. Prog Neuropsychopharmacol Biol Psychiatry. 2002 Dec;26(7-8):1235-43 - PubMed
  6. CNS Drug Rev. 2006 Summer;12 (2):123-34 - PubMed

Publication Types